Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Cancer/Tumors Clinical Trials

A listing of Cancer/Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (43) clinical trials

Patients who wish to enroll in a research study should discuss the possibilities with their urologist. The TUCC Clinical Research Department staff remains in constant communication with patients throughout their enrollment in clinical trials. These patients receive all study related medication and procedures at no cost. Participation is voluntary and ...


Smartphone Technology to Alleviate Malignant Pain (STAMP)

The purpose of the study is to develop the STAMP app (Smartphone Technology to Alleviate Malignant Pain). This app will be used by patients with advanced cancer to track symptoms and receive tailored symptom management advice. This project will involve 4 specific activities: Activity 1 - Content Development (working groups) ...

Phase N/A

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Breast cancer can be categorized into four clinical subsets based on the expression of hormone receptors (HR), such as the estrogen receptor (ER) and/or progesterone receptor (PR), and expression or gene amplification of the oncogene HER2. Treatment of these clinical subsets differs: ER/PR-positive breast cancer is managed primarily with endocrine ...

Phase N/A

PTFE Stents for Treatment of Malignant Biliary Strictures

ERCP (endoscopic retrograde cholangiopancreatography) is the standard method of treating diseases in the biliopancreatic system and the treatment goal is achieved in a very high proportion of the studies. The ERCP is based on the indirect imaging of the bile ducts by injection of contrast medium, which is visualized in ...

Phase N/A

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting

This is an open-label, multicenter, Phase 2 study to assess the safety and antitumor activity in adult patients with relapsed or refractory B-cell non-Hodgkin Lymphoma when administered with lisocabtagene maraleucel (JCAR017) in the outpatient setting. Upon the successful product generation of lisocabtagene maraleucel, subjects will enter the treatment phase of ...


Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

<Research Hypothesis> The dynamics of immune cells by CCRT/Durvalumab will be uncovered. The combination of Durvalumab with concurrent chemoradiotherapy (CCRT/gemcitabine)) as neoaduvant treatment in resectable or borderline resectable pancreatic cancer is feasible and efficacious. The combination of Durvalumab with cytotoxic chemotherapy (gemcitabine) as an adjuvant treatment is feasible and efficacious. ...


Treatment With Immunological Checkpoint Inhibitors of HIV-infected Subjects With Cancer

Long-lived latently infected resting CD4+ T cells are the main reason why current antiretroviral therapy (ART) is unable to cure HIV infection. Recent work has suggested that the expression of immune checkpoint markers, such as the programmed death-1 (PD1) or the cytotoxic T-lymphocyte antigen 4 (CTL-4), may play a role ...

Phase N/A

Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock

An interim analysis planned after inclusion of 233 patients.


Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid Leukemia

Participants receive gemtuzumab ozogamicin intravenously (IV) on days 1, 4, 7. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Non-responders without significant adverse events during the first course and responders, may receive a second course of gemtuzumab ozogamicin within 60 days after course 1. ...